A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?

Front Endocrinol (Lausanne). 2022 Mar 1:13:798975. doi: 10.3389/fendo.2022.798975. eCollection 2022.

Abstract

Aim: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer.

Methods: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects.

Results: The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively.

Discussion: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.

Keywords: COVID-19 vaccine; Iran; SARS-CoV2; breast cancer; cancer; inactivated SARS-CoV-2 vaccine; malignancy; seroconversion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral
  • Breast Neoplasms*
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Cohort Studies
  • Female
  • Humans
  • Middle Aged
  • RNA, Viral
  • SARS-CoV-2
  • Trastuzumab

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • RNA, Viral
  • Trastuzumab